Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
23 hedge funds and large institutions have $5.04M invested in Celgene Corporation Contingent Value Rights in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
8% less funds holding
Funds holding: 25 → 23 (-2)
10% less capital invested
Capital invested by funds: $5.61M → $5.04M (-$569K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
FCG Advisors
Chatham,
New Jersey
|
+$114K |
| 2 |
First Manhattan
New York
|
+$69.5K |
| 3 |
WJA
Williams Jones & Associates
New York
|
+$34.8K |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
+$15.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$423K |
| 2 |
Millennium Management
New York
|
-$202K |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$178K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$99K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$57.6K |
CELGZ Hedge Fund Activity: Q1 2014 in Review
23 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q1 2014, worth a combined $5.04M — down 10% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CELGZ and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was FCG Advisors, adding an estimated $114K. The largest seller was Opaleye Management, cutting an estimated $423K.
- 23 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q1 2014, down from 25 in Q4 2013.
- Funds reported $5.04M of Celgene Corporation Contingent Value Rights stock for Q1 2014, down 10% quarter-over-quarter.
- 1 fund opened new Celgene Corporation Contingent Value Rights positions in Q1 2014 and 3 closed out, a net change of -2 holders.
- The largest Celgene Corporation Contingent Value Rights buyer in Q1 2014 was FCG Advisors, an estimated $114K added.
- The largest Celgene Corporation Contingent Value Rights seller in Q1 2014 was Opaleye Management, an estimated $423K sold.
Based on aggregated 13F filings for Q1 2014.